Answers are grounded in this paper and cite their sources.
The production of protein-based medical agents, like monoclonal antibodies (Mabs), by biotechnological processes requires a comprehensive quality control. The pharmaceutical industry and national health authorities support the complete characterization of therapeutic proteins to increase the quality and safety. During numerous and different production steps like fermentation, purification and storage, various protein modifications on therapeutic products can occur, like deamidation of asparagine and glutamine, oxidation of methionine tryptophan residues, clipping of terminal amino acids, glycation and others.
No takes yet. Share an insight, caveat, or question.
Hakemeyer et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: